ClotChek clotting times showed good sensitivity and specificity to identify meaningful anticoagulation among patients taking apixaban or rivaroxaban, and could aid physicians at the point of care in making therapeutic decisions in patients with adverse events associated with oral factor Xa inhibitors.
S. Bakhru, Jean M. Connors, Robert P. Giugliano et al.· Thrombosis and Haemostasis· 0 citations
Extracranial clinically relevant bleeding is common among patients with AF treated with OACs and may more accurately reflect the overall burden of bleeding than major bleeding alone, suggesting that additional unmeasured or unknown factors contribute to bleeding risk.
Deborah M. Siegal, Marc Carrier, M. Bahit et al.· Circulation· 0 citations
ClotChek clotting times showed good sensitivity and specificity to identify meaningful anticoagulation among patients taking apixaban or rivaroxaban, and could aid physicians at the point of care in making therapeutic decisions in patients with adverse events associated with oral factor Xa inhibitors.
S. Bakhru, Jean M. Connors, Robert P. Giugliano et al.· 0 citations
Perceived risk of bleeding was the leading cause for non-treatment with OACs in high-risk AF patients, and risk prediction modelling indicated that the benefits of anticoagulation in stroke and mortality reduction outweigh the risk of bleeding.
A. Kakkar, Marc P Bonaca, Robert P. Giugliano et al.· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
